Head, Clinical Research
Professor Robert Booy
Our burgeoning research role has and continues to underpin the introduction of new vaccines and evaluation of ongoing programs.
We are generating innovative work examining the safety, efficacy, effectiveness and cost-effectiveness of new immunoprophylactics for evermore diseases.
This occurs alongside cutting-edge work in mathematical and economic modelling, systematic literature reviews and interventional studies to address the value of vaccines as well as physical and pharmaceutical measures for preventing infectious diseases.
Given the myriad of potentially life threatening infections, a list constantly expanding as humans fall prey to new animal-acquired diseases, how can we prioritise our program of work? Given that our major focus is on diseases for which there are already strong vaccine candidates, we have further focused on researching those infections with the greatest mortality and morbidity in the Australian setting, either because of the pathogen itself or because of the vulnerable nature of the host.
As a result, we have conducted a series of studies primarily focused on vaccines but also including other means of disease prevention such as antiviral agents and masks.
Studies have been in the young, the old and immunocompromised people and have covered influenza, meningococcal disease, pneumococcal disease, pertussis, hepatitis B, varicella-zoster (shingles) and human papillomavirus.